Cabaletta Bio, Inc.

NasdaqGS:CABA Stock Report

Market Cap: US$114.4m

Cabaletta Bio Management

Management criteria checks 2/4

Cabaletta Bio's CEO is Steven Nichtberger, appointed in Jan 2017, has a tenure of 7.92 years. total yearly compensation is $4.81M, comprised of 12.4% salary and 87.6% bonuses, including company stock and options. directly owns 2.76% of the company’s shares, worth $3.16M. The average tenure of the management team and the board of directors is 3.1 years and 4.9 years respectively.

Key information

Steven Nichtberger

Chief executive officer

US$4.8m

Total compensation

CEO salary percentage12.4%
CEO tenure7.9yrs
CEO ownership2.8%
Management average tenure3.1yrs
Board average tenure4.9yrs

Recent management updates

Recent updates

Is Cabaletta Bio (NASDAQ:CABA) In A Good Position To Invest In Growth?

Dec 10
Is Cabaletta Bio (NASDAQ:CABA) In A Good Position To Invest In Growth?

Cabaletta: Biotech With Large Potential, Interesting Bottom Pattern, Plenty Of Cash

Oct 22

We're Hopeful That Cabaletta Bio (NASDAQ:CABA) Will Use Its Cash Wisely

Sep 04
We're Hopeful That Cabaletta Bio (NASDAQ:CABA) Will Use Its Cash Wisely

Cabaletta Bio: Next Data Readout Needs To Be Mic Drop Moment

Jun 28

Cabaletta Bio (NASDAQ:CABA) Is In A Good Position To Deliver On Growth Plans

May 22
Cabaletta Bio (NASDAQ:CABA) Is In A Good Position To Deliver On Growth Plans

Cabaletta Bio: Two Differentiated CAR-T Platforms To Carry It Forward

Jan 31

Cabaletta Bio (NASDAQ:CABA) Is In A Good Position To Deliver On Growth Plans

Dec 28
Cabaletta Bio (NASDAQ:CABA) Is In A Good Position To Deliver On Growth Plans

Here's Why We're Not Too Worried About Cabaletta Bio's (NASDAQ:CABA) Cash Burn Situation

Sep 12
Here's Why We're Not Too Worried About Cabaletta Bio's (NASDAQ:CABA) Cash Burn Situation

Here's Why We're Not Too Worried About Cabaletta Bio's (NASDAQ:CABA) Cash Burn Situation

Jun 04
Here's Why We're Not Too Worried About Cabaletta Bio's (NASDAQ:CABA) Cash Burn Situation

Cabaletta Bio (NASDAQ:CABA) Is In A Good Position To Deliver On Growth Plans

Feb 11
Cabaletta Bio (NASDAQ:CABA) Is In A Good Position To Deliver On Growth Plans

We Think Cabaletta Bio (NASDAQ:CABA) Needs To Drive Business Growth Carefully

Oct 20
We Think Cabaletta Bio (NASDAQ:CABA) Needs To Drive Business Growth Carefully

We Think Cabaletta Bio (NASDAQ:CABA) Needs To Drive Business Growth Carefully

Jul 07
We Think Cabaletta Bio (NASDAQ:CABA) Needs To Drive Business Growth Carefully

Cabaletta Bio (NASDAQ:CABA) Is In A Good Position To Deliver On Growth Plans

Mar 24
Cabaletta Bio (NASDAQ:CABA) Is In A Good Position To Deliver On Growth Plans

We're Hopeful That Cabaletta Bio (NASDAQ:CABA) Will Use Its Cash Wisely

Dec 09
We're Hopeful That Cabaletta Bio (NASDAQ:CABA) Will Use Its Cash Wisely

We're Not Very Worried About Cabaletta Bio's (NASDAQ:CABA) Cash Burn Rate

Aug 05
We're Not Very Worried About Cabaletta Bio's (NASDAQ:CABA) Cash Burn Rate

Cabaletta Bio EPS beats by $0.08

May 03

Cabaletta Bio (NASDAQ:CABA) Is In A Good Position To Deliver On Growth Plans

Apr 12
Cabaletta Bio (NASDAQ:CABA) Is In A Good Position To Deliver On Growth Plans

What Percentage Of Cabaletta Bio, Inc. (NASDAQ:CABA) Shares Do Insiders Own?

Feb 19
What Percentage Of Cabaletta Bio, Inc. (NASDAQ:CABA) Shares Do Insiders Own?

Chardan Capital initiates Cabaletta Bio with Buy rating

Jan 08

We're Hopeful That Cabaletta Bio (NASDAQ:CABA) Will Use Its Cash Wisely

Dec 28
We're Hopeful That Cabaletta Bio (NASDAQ:CABA) Will Use Its Cash Wisely

Dosing underway in Cabaletta Bio's DSG3-CAART study in a rare skin blistering disorder

Dec 09

Cabaletta Bio +5% on Q3 results, pipeline update

Nov 10

CEO Compensation Analysis

How has Steven Nichtberger's remuneration changed compared to Cabaletta Bio's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-US$104m

Jun 30 2024n/an/a

-US$90m

Mar 31 2024n/an/a

-US$77m

Dec 31 2023US$5mUS$597k

-US$68m

Sep 30 2023n/an/a

-US$62m

Jun 30 2023n/an/a

-US$57m

Mar 31 2023n/an/a

-US$56m

Dec 31 2022US$2mUS$569k

-US$53m

Sep 30 2022n/an/a

-US$51m

Jun 30 2022n/an/a

-US$51m

Mar 31 2022n/an/a

-US$50m

Dec 31 2021US$4mUS$542k

-US$46m

Sep 30 2021n/an/a

-US$42m

Jun 30 2021n/an/a

-US$39m

Mar 31 2021n/an/a

-US$36m

Dec 31 2020US$4mUS$516k

-US$33m

Sep 30 2020n/an/a

-US$29m

Jun 30 2020n/an/a

-US$26m

Mar 31 2020n/an/a

-US$21m

Dec 31 2019US$1mUS$437k

-US$22m

Sep 30 2019n/an/a

-US$19m

Jun 30 2019n/an/a

-US$23m

Mar 31 2019n/an/a

-US$21m

Dec 31 2018US$1mUS$213k

-US$12m

Compensation vs Market: Steven's total compensation ($USD4.81M) is above average for companies of similar size in the US market ($USD653.16K).

Compensation vs Earnings: Steven's compensation has increased whilst the company is unprofitable.

CEO

Steven Nichtberger (63 yo)

7.9yrs

Tenure

US$4,808,279

Compensation

Dr. Steven A. Nichtberger, M.D., serves as managing partner of GBF Advisors, LLC. Dr. Nichtberger is an adjunct professor at The Wharton School at the University of Pennsylvania. He is Co-Founder of Cabale...

Leadership Team

NamePositionTenureCompensationOwnership
Steven Nichtberger
Co-Founder7.9yrsUS$4.81m2.76%
$ 3.2m
David Chang
Chief Medical Officer5.5yrsUS$2.10m0%
$ 0
Gwendolyn Binder
President of Science & Technologyno dataUS$2.34m0.041%
$ 46.8k
Michael Milone
Co-Founder & Co-Chair of Scientific Advisory Boardno datano datano data
Aimee Payne
Co-Founder & Co-Chair of Scientific Advisory Boardno datano datano data
Anup Marda
Chief Financial Officer5.9yrsUS$1.53mno data
Qing Yuan
Chief Technology Officerless than a yearno datano data
Samik Basu
Chief Scientific Officer3.1yrsno datano data
Michael Gerard
General Counsel & Secretary3.3yrsno datano data
Heather Harte-Hall
Chief Compliance Officer3.1yrsno datano data
Nicolette Sherman
Chief Human Resources Officerless than a yearno datano data
Arun Das
Chief Business Officer2.9yrsno datano data

3.1yrs

Average Tenure

51yo

Average Age

Experienced Management: CABA's management team is considered experienced (3.1 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Steven Nichtberger
Co-Founder7.9yrsUS$4.81m2.76%
$ 3.2m
Michael Milone
Co-Founder & Co-Chair of Scientific Advisory Boardno datano datano data
Aimee Payne
Co-Founder & Co-Chair of Scientific Advisory Boardno datano datano data
Richard Henriques
Independent Director5.8yrsUS$259.20k0%
$ 0
Carl June
Member of Scientific Advisory Board4.3yrsno datano data
Mark Simon
Independent Director6.2yrsUS$260.15k0.29%
$ 335.0k
Brian Daniels
Member of Scientific Advisory Board3.5yrsUS$202.24kno data
Scott Brun
Independent Director3.5yrsUS$255.83k0%
$ 0
Iain McInnes
Member of Scientific Advisory Board4.9yrsno datano data
Jay Siegel
Member of Scientific Advisory Boardno datano datano data
Drew Weissman
Member of Scientific Advisory Board3yrsno datano data
Catherine Bollard
Independent Director5.7yrsUS$255.43k0.0021%
$ 2.3k

4.9yrs

Average Tenure

63yo

Average Age

Experienced Board: CABA's board of directors are considered experienced (4.9 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/24 22:17
End of Day Share Price 2024/12/24 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Cabaletta Bio, Inc. is covered by 13 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Joshua SchimmerCantor Fitzgerald & Co.
Samantha Lynn SemenkowCitigroup Inc
Joshua SchimmerEvercore ISI